The narrowed FY 2026 operating income outlook to flat/negative mid-single-digit growth signals continued headwinds from TDAPA regulations and inflation. Monitor Q4 results for the full-year exit rate and any further guidance revision. The 5008X CAREsystem rollout and FME25+ savings program are positive offsets but not yet sufficient to reverse the earnings decline.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $21.73entry
- T+1 · 13d ago +6.72%α +5.07% · $23.19
- T+5 · 7d ago +4.65%α +5.24% · $22.74
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Fresenius Medical Care reported Q3 2026 revenue of EUR 4,937M (+1% YoY, -1% constant currency) and adjusted EPS (excl. special items) of EUR 1.11, flat YoY. Reported GAAP EPS fell 35% to EUR 0.61 due to EUR 108M in one-time China restructuring charges. The company narrowed its full-year 2026 operating income outlook to between flat and a negative mid-single-digit percent growth rate, citing regulatory headwinds and inflation.
Key Financial Metrics
Key Facts
- Q3 2026 revenue EUR 4,937M, +1% YoY reported, -1% constant currency
- Reported GAAP EPS EUR 0.61, -35% YoY; adjusted EPS EUR 1.11, flat YoY
- Reported operating income EUR 384M, -19% YoY; adjusted operating income EUR 545M, -5% YoY
- Reported net income EUR 160M, -42% YoY; adjusted net income EUR 291M, -10% YoY
- China strategy refinement caused EUR 108M one-time costs (impairments, scrappage, termination)
- FY 2026 operating income outlook narrowed to flat to negative mid-single-digit percent growth (from prior range)
- Revenue outlook unchanged at broadly flat for FY 2026
- U.S. same-market treatment growth -1.1% in Q3; international same-market treatment growth +1.4%
- Operating cash flow EUR 798M, +8% YoY; free cash flow EUR 564M, +3% YoY
- Net leverage ratio stable at 2.6x, within 2.5x-3.0x target band
- Share buyback: 9.1M shares (3.4% of total) repurchased for EUR 357M as of Sep 30
- 5008X CAREsystem rollout: 348 U.S. clinics converted, 1.3M treatments performed
Financial Impact
EUR 108M one-time China restructuring charges; adjusted operating income margin declined 70 bps to 11.0%
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Care Delivery | $3.5B | +2.7% |
| Value-Based Care | $537.0M | -6.8% |
| Care Enablement | $1.5B | +6.7% |
Risk Factors
- TDAPA reimbursement regulations continue to pressure U.S. Care Delivery revenue
- China strategy refinement may lead to further charges or revenue loss
- U.S. same-market treatment growth negative at -1.1%, indicating patient volume decline
- Currency headwinds (EUR strength) negatively impacted reported revenue and earnings
- Inflationary cost increases, especially labor, are pressuring margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-121625 |
| Document: tm2628784d1_ex99-2.htm | 0001104659-26-121625 |
| Document: tm2628784d1_6k.htm | 0001104659-26-121625 |
| Document: 0001104659-26-121625-index-headers.html | 0001104659-26-121625 |
| Document: 0001104659-26-121625-index.html | 0001104659-26-121625 |
| Document: 0001104659-26-121625.txt | 0001104659-26-121625 |
| Earnings Context (Synthetic; results releases only) | 0001104659-26-121625 |
Track record
16 reports on FMS
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +3.43% at T+60 after the Apr 7, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13D/A Bearish 5/10 Entry $22.03 Now $21.86 +0.77% settles Nov 20
- Nov 9, 20267d ago 6-K Neutral 2/10 Entry $22.95 to $21.86 Now $21.86 −4.75% ▼ −4.75% −3.06% vs SPY
- Nov 3, 202613d ago 6-K Bearish 6/10 No price data
- Nov 3, 202613d ago 6-K Bearish 5/10 Viewing Entry $21.73 to $22.74 Now $21.86 −0.60% ▼ −4.65% −5.24% vs SPY
- Oct 30, 202618d ago Court Ruling Neutral 4/10 Entry $22.61 to $22.95 Now $21.86 −3.32% ▲ +1.50% +1.43% vs SPY
- Oct 7, 20265w ago 6-K Neutral 3/10 Entry $20.69 to $21.54 Now $21.86 +5.65% ▲ +4.11% +5.09% vs SPY
- Sep 25, 20267w ago 6-K Bearish 5/10 Entry $22.69 to $22.25 Now $21.86 +3.66% ▲ +1.94% +1.72% vs SPY
- Sep 1, 202611w ago Court Ruling Neutral 1/10 Entry $22.65 to $22.23 Now $21.86 −3.49% ▼ −1.85% −0.90% vs SPY
- Aug 31, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 4/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers